Skip to content

The Effect of melatonin in the Treatment of Sepsis and Septic Shock

Study of the melatonin effect compared to placebo on disease improvement in adult patients with sepsis and septic shock: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210530051444N1
Enrollment
74
Registered
2025-04-16
Start date
2025-04-05
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe sepsis with septic shock. Severe sepsis with septic shock

Interventions

Intervention 1: Intervention group: Routine treatment plus oral melatonin 10 mg manufactured by Jalinous Pharmaceutical Factory, 2 tablets orally every night for 5 days. Intervention 2: Control group:

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 years and older Diagnosed with sepsis or septic shock within 24 hours or more of ICU admission Patients who themselves or their legal guardian sign the informed consent form Able to swallow or have an NG tube

Exclusion criteria

Exclusion criteria: Patients who have a history of allergy and sensitivity to melatonin or any of its components Pregnant and lactating patients patients with End-stage renal disease requiring hemodialysis

Design outcomes

Primary

MeasureTime frame
Event of Death. Timepoint: From ICU admission to discharge, on a daily basis. Method of measurement: By clinical observation.;Duration of hospitalization. Timepoint: From hospital admission to discharge, on a daily basis. Method of measurement: By clinical observation.;Duration of ICU stay. Timepoint: From ICU admission to discharge from ICU , on a daily basis. Method of measurement: By clinical observation.;Vasopressor Requirement. Timepoint: During ICU stay, based on the days vasopressors are received. Method of measurement: Clinical observation and medical records.

Secondary

MeasureTime frame
Acute Kidney Injury Incidence. Timepoint: In the beginning and every 48 hours thereafter. Method of measurement: Clinical observation and laboratory tests.;Need for Hemodialysis. Timepoint: In the beginning and every 48 hours thereafter. Method of measurement: Clinical observation and hospital records.;APACHE II Score. Timepoint: At the beginning of treatment. Method of measurement: Clinical assessment and laboratory data.;SOFA Score. Timepoint: On days 1, 3, 5, 7, 10, and so on, throughout the ICU stay. Method of measurement: Clinical assessment and laboratory data.;Duration of Mechanical Ventilation. Timepoint: During ICU stay, based on the days ventilator support is provided. Method of measurement: Clinical observation and medical records.;Serum Procalcitonin Level. Timepoint: At the beginning and on day 5 of treatment. Method of measurement: Blood test.;C-Reactive protein. Timepoint: At the beginning and on day 5 of treatment. Method of measurement: Blood test.;Body temperature. Timepoint: In the beginning and every 48 hours thereafter. Method of measurement: Thermometer.;White Blood Cell Count. Timepoint: In the beginning and every 48 hours thereafter. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaleh Mahmoudi

Shiraz University of Medical Sciences

mahmoudi_l@sums.ac.ir+98 71 3242 4127

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026